Arcturus Therapeutics Holdings Inc.

ARCT Nasdaq SEC CIK 1768224
Follow Arcturus Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $18.3M +6.7% vs same quarter last year
Net income −$7.4M +44.9% vs same quarter last year
EPS, diluted −$0.26 +46.9% vs same quarter last year
Operating cash flow −$6.9M +59.7% vs same quarter last year
Revenue by quarter
$22.8M
$29.4M
$28.3M
$17.2M
$7.2M
$2.1M
$3M
$18.3M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income9 fiscal years
  • Revenue
  • Net income
−$400M−$200M$0$200M$400MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$82M−$65.8M
FY24$152.3M−$80.9M
FY23$166.8M−$29.7M
FY22$206M$9.3M
FY21$12.4M−$203.7M
FY20$9.5M−$72.1M
FY19$20.8M−$26M
FY18$15.8M−$21.8M
FY17--
MarginsShare of revenue
  • Operating margin
  • Net margin
−2000%−1500%−1000%−500%0%500%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25−93%−80.2%
FY24−62.8%−53.1%
FY23−46.9%−17.8%
FY225.9%4.5%
FY21−1641.3%−1648%
FY20−749.8%−756.3%
FY19−122.7%−125%
FY18−138.5%−138.3%
FY17--
Free cash flowOperating cash flow minus capital expenditure
−$150M−$100M−$50M$0$50MFY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$74.5M
FY24−$60.4M
FY23−$21M
FY22$24.3M
FY21−$138.4M
FY20−$44.6M
FY19−$7.3M
FY18−$22.2M
FY17-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Arcturus Therapeutics
  • Healthcare median
−2000%−1500%−1000%−500%0%500%FY17FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearArcturus TherapeuticsHealthcare median
FY25−80.2%−30.6%
FY24−53.1%−47%
FY23−17.8%−58%
FY224.5%−80.4%
FY21−1648%−71.8%
FY20−756.3%−62.2%
FY19−125%−46.2%
FY18−138.3%−49.6%
FY17-−45.9%